Skip to main content
OpenTrials
Completed

NCT Number: NCT04779905

Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with metabolic syndrome, obesity, and type II diabetes. NAFLD is considered to be an independent risk factor for cardiovascular disease and there is accumulating evidence to support a causative role in the development of chronic kidney disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD patients

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021 to July 2021.

Methods:

All included patients will be subjected to:

  • Detailed history, complete general and systemic examination .
  • BMI will be calculated as follow
  • Abdominal Ultrasonography.
  • Laboratory investigations:

Fasting and post-prandial blood sugar Serum lipogram. Liver function tests. Serum creatinine, Albumin -creatinine Ratio.

  • Calculation of estimated Glomerular Filtration Rate eGFR.
  • Liver stiffness measurements to detect degree of fibrosis and measurement of the degree of steatosis using (Fibroscan)

Ethical considerations:

The study will be approved by The Ethical committee of Sohag Faculty of Medicine, Sohag University.

The study protocol will be adherent to practice guidelines of the World Medical Association Code of Ethics (Declaration of Helsinki).

After explanation about the nature of the procedures, possible complications, benefits, and steps of the study, All patients will give a written informed consent for participating in the study, performing abdominal ultrasound, taking blood samples, performing fibroscan.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital

Exclusion criteria

  • Diabetic patients.
  • Hypertensive patients.
  • Other causes of chronic liver disease rather than NAFLD.

Treatment and study plan

urinary albumbin/creatinine ratio

Diagnostic Test

detection of microalbuminuria in nafld patients

Other names: estimated glomerular filtration rate

Primary outcomes

  1. prevalence of chronic kidney disease in nafld patient

    Time frame: February 2021 to July 2021

  2. correlation of chronic kidney disease and degree of hepatic fibrosis in nafld patient

    Time frame: February 2021 to July 2021

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients

Acronym: NAFLD

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Mar 3, 2021
Registry last updated
Nov 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.